Nonalcoholic fatty liver disease (NAFLD) and cryptogenic cirrhosis (CC) are considered preneoplastic conditions that might progress to hepatocellular carcinoma. We evaluated parameters of telomere dysfunction in these patient groups to study the correlation between telomere length and the progression of NAFLD. We analyzed peripheral lymphocytes from 22 patients with NAFLD, 20 patients with CC, and 20 healthy, age-matched controls. Telomere length was analyzed using quantitative fluorescence in situ hybridization, and cellular senescence was evaluated by the percentage of cells with senescence-associated heterochromatin foci. The expression of telomerase reverse transcriptase (hTERT) mRNA was measured using polymerase chain reaction, and telomere capture (TC) was assessed with 2 Cytocell probes, 15qter and 13qter. Shorter telomere length and increased cellular senescence was demonstrated in patients with NAFLD, compared to the CC patients and healthy controls. While hTERT mRNA was significantly decreased, TC was increased in CC patients, compared to the NAFLD group and healthy individuals. Thus, there is a correlation between hTERT mRNA expression and telomere length in patients with NAFLD, which might be related to associated metabolic disorders and the risk of malignant transformation. Patients with CC, on the contrary, elongate their telomeres through the TC mechanism.

Keywords:
Cryptogenic cirrhosis, Fatty liver, Fluorescence in situ hybridization, Telomeres
1.
Abdelmalek M, Ludwig J, Lindor KD: Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 20:127-130 (1995).
2.
Amiel A, Goldzak G, Gaber E, Yosef G, Fejgin MD, et al: Random aneuploidy and telomere capture in chronic lymphocytic leukemia and chronic myeloid leukemia patients. Cancer Genet Cytogenet 163:12-16 (2005).
3.
Aravinthan A, Scarpini C, Tachtatzis P, Verma S, Penrhyn-Lowe S, et al: Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol 58:549-556 (2013).
4.
Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al: Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356:1317-1326 (2007).
5.
Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972-1978 (2010).
6.
Atkinson SP, Hoare SF, Glasspool RM, Keith WN: Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65:7585-7590 (2005).
7.
Ben-Porath I, Weinberg RA: The signals and pathways activating cellular senescence. Int J Biochm Cell Biol 37:961-976 (2005).
8.
Calado RT, Brudno J, Mehta P, Kovacs JJ, Wu C, et al: Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 53:1600-1607 (2011).
9.
Cao Y, Bryan TM, Reddel RR: Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci 99:1092-1099 (2008).
10.
Chaiteerakij R, Roberts LR: Telomerase mutation: a genetic risk factor for cirrhosis. Hepatology 53:1430-1432 (2011).
11.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al: The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005-2023 (2012).
12.
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, et al: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921-1929 (1992).
13.
Friedrich U, Griese E, Schwab M, Fritz P, Thon K, Klotz U: Telomere length in different tissues of elderly patients. Mech Ageing Dev 119:89-99 (2000).
14.
Georgin-Lavialle S, Aouba A, Mouthon L, Londono-Vallejo JA, Lepelletier Y, Gabet AS, et al: The telomere/telomerase system in autoimmune and systemic immune-mediated diseases. Autoimmun Rev 9:646-651 (2010).
15.
Goldberg-Bittman L, Amiel A, Hadary R, Fejgin MD, Quitt M, Kitay-Cohen Y: Telomere capture in hepatitis C infection. Cancer Genet Cytogenet 191:63-66 (2009).
16.
Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345:458-460 (1990).
17.
Hug N, Lingner J: Telomere length homeostasis. Chromosoma 115:413-425 (2006).
18.
Kim H, Oh BK, Roncalli M, Park C, Yoon SM, et al: Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology 50:752-762 (2009).
19.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015 (1994).
20.
Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, et al: A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 28:3765-3774 (2009).
21.
Laish I, Katz H, Stein A, Liberman M, Naftali T, et al: Telomere dysfunction in peripheral blood lymphocytes from patients with primary sclerosing cholangitis and inflammatory bowel disease. Dig Liver Dis 47:790-796 (2015).
22.
Ma D, Zhu W, Hu S, Yu X, Yang Y: Association between oxidative stress and telomere length in type 1 and type 2 diabetic patients. J Endocrinol Invest 36:1032-1037 (2013).
23.
MacIntyre A, Brouilette SW, Lamb K, Radhakrishnan K, McGlynn L, et al: Association of increased telomere length in limited scleroderma, with a lack of age-related telomere erosion. Ann Rheum Dis 67:1780-1782 (2008).
24.
Meltzer PS, Guan X, Trent JM: Telomere capture stabilizes chromosome breakage. Nat Genet 4:252-255 (1993).
25.
Nakajima T, Moriguchi M, Katagishi T, Sekoguchi S, Nishikawa T, et al: Premature telomere shortening and impaired regenerative response in hepatocytes of individuals with NAFLD. Liver Int 26:23-31 (2006).
26.
Narita M, Narita M, Krizhanovsky V, Nuñez S, Chicas A, et al: A novel role for high-mobility group A proteins in cellular senescence and heterochromatin formation. Cell 126:503-514 (2006).
27.
Oikawa S, Tada-Oikawa S, Kawanishi S: Site-specific DNA damage at the GGG sequence by UVA involves acceleration of telomere shortening. Biochemistry 40:4763-4768 (2001).
28.
Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, et al: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49:851-859 (2009).
29.
Plentz RR, Caselitz M, Bleck JS, Gebel M, Flemming P, et al: Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40:80-86 (2004).
30.
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74-80 (1990).
31.
Preston RJ: Telomeres, telomerase and chromosome stability. Radiat Res 147:529-534 (1997).
32.
Révész D, Milaneschi Y, Verhoeven JE, Penninx BW: Telomere length as a marker of cellular ageing is associated with prevalence and progression of metabolic syndrome. J Clin Endocrinol Metab 99:4607-4615 (2014).
33.
Rode L, Nordestgaard BG, Weischer M, Bojesen SE: Increased body mass index, elevated C-reactive protein, and short telomere length. J Clin Endocrinol Metab 99:E1671-1675 (2014).
34.
Shiloh Y: The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31:402-410 (2006).
35.
Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274-285 (2011).
36.
Volpi A, Bravaccini S, Medri L, Cerasoli S, Gaudio M, Amadori D: Usefulness of immunological detection of the human telomerase reverse transcriptase. Cell Oncol 27:347-353 (2005).
37.
von Zglinicki T: Oxidative stress shortens telomeres. Trends Biochem Sci 27:339-344 (2002).
38.
Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, et al: Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 16:935-942 (2002).
39.
Wiemann SU, Satyanarayana A, Buer J, Kamino K, Manns MP, Rudolph KL: Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage. Oncogene 24:1501-1509 (2005).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.